Biocon Ltd Share Price (BIOCON)

Biocon Signs Licensing Agreement with Biomm for Commercialisation of Semaglutide in Brazil - 18 Apr, 2024

Biocon has signed a licensing and supply agreement with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Biocon will undertake development, manufacturing and supply of the drug product, while Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market. The potential market for Semaglutide in Brazil stands at around $580 million.

Biocon Partners with Biomm SA for Diabetes Drug Commercialisation in Brazil - 17 Apr, 2024

Biocon has partnered with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Meanwhile, ICICI Securities expects Biocon's Q4 net profit to be at Rs 67.1 crore, down 192.8% YoY.

Biocon Pivots to Anti-Obesity Therapies Amid Patent Expirations - 08 Apr, 2024

Biocon Ltd is leading Indian drugmakers in the race to grab a slice of the $100 billion obesity drugs market, as patents for blockbuster medications start to expire. Biocon has scored an early win among its peers with UK approval for the first generic version of liraglutide injectable.

Biocon Transfers Branded Formulations Business to Eris Lifesciences - 03 Apr, 2024

Biocon Biologics has completed the transfer of its branded formulations business in India to Eris Lifesciences for Rs 1,242 crore. The transaction was conducted on a slump sale basis and includes metabolics, oncology, and critical care diagnostics.

Biocon Receives Approval for gSaxenda Formulation - 01 Apr, 2024

Biocon's complex formulation Liraglutide (gSaxenda) has received approval from MHRA, UK, leading to a 1.7% rise in the company's stock. The pharmaceuticals and drugs sector saw investments exceeding expectations, with Biocon being one of the major beneficiaries. In Q3 FY24, Biocon reported a consolidated net profit of Rs 660 crore.

Biocon Receives Approval for Diabetes Drug Liraglutide in UK - 28 Mar, 2024

Biocon Ltd has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for its complex formulation Liraglutide used in treating Type-2 Diabetes Mellitus. The approval is an important milestone as it strengthens Biocon's leadership in delivering many firsts on complex drug products. Shares rose by over 3%. Biocon's operating revenues and profit figures have shown a stellar performance during recent financial quarters.

Biocon Stock Rises as Bernstein Maintains Ratings - 27 Mar, 2024

Biocon Ltd's stock rises for the fifth consecutive day, while foreign brokerage firm Bernstein maintains its outperform and underperform ratings on major pharmaceutical companies.

Biocon Ltd Stock Up 1.83% on NSE - 22 Mar, 2024

Biocon Ltd stock is up 1.83% on the NSE, trading at Rs 253.25 as of 12:49 IST. The stock has gained 22.34% in the last year compared to a 29.37% jump in NIFTY and a 59.35% jump in the Nifty Pharma index.

Biocon Stock Faces Resistance and Likely to Decline Further - 21 Mar, 2024

Biocon Ltd's stock has been facing strong resistance at ₹290 and is expected to decline further according to technical analysis. Traders are advised to go short on the stock with a target price of ₹240.

Biocon Ltd Shows Strong Growth in EPS, EBIT Margins and Revenues - 20 Mar, 2024

Biocon Ltd has shown impressive growth in EPS, with a compound annual growth rate of 26% over the last three years. Additionally, EBIT margins have grown from 12% to 14% in the past year, while revenues are on an upward trend. Insiders own a significant share of the company at 63%.